Ivacaftor for patients with cystic fibrosis

@article{Wainwright2014IvacaftorFP,
  title={Ivacaftor for patients with cystic fibrosis},
  author={C. Wainwright},
  journal={Expert Review of Respiratory Medicine},
  year={2014},
  volume={8},
  pages={533 - 538}
}
  • C. Wainwright
  • Published 2014
  • Medicine
  • Expert Review of Respiratory Medicine
  • Ivacaftor is an oral bioavailable potentiator of the cystic fibrosis transmembrane conductance regulator protein. It is the first therapeutic agent that has been registered for clinical use which targets the basic defect in people with cystic fibrosis who carry a G551D mutation or other rarer specific gating mutations. Clinical trials have shown consistent and impressive clinical benefit that appears to be sustained over time in people with cystic fibrosis who carry a G551D mutation and similar… CONTINUE READING
    13 Citations

    Topics from this paper

    Hallmarks of therapeutic management of the cystic fibrosis functional landscape.
    • M. Amaral, W. Balch
    • Medicine
    • Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
    • 2015
    • 35
    Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients.
    • 54
    Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States.
    • 5
    Nasospheroids permit measurements of CFTR-dependent fluid transport.
    • 18
    • PDF
    Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment
    • 16
    Structural Changes Fundamental to Gating of the Cystic Fibrosis Transmembrane Conductance Regulator Anion Channel Pore.
    • P. Linsdell
    • Chemistry, Medicine
    • Advances in experimental medicine and biology
    • 2017
    • 6

    References

    SHOWING 1-10 OF 33 REFERENCES
    Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
    • 342
    A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    • 1,435
    • PDF
    Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    • 462
    • PDF
    The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D).
    • 18
    Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.
    • 109